Effectiveness and safety of artesunate–amodiaquine versus artemether–lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6–120 months in Yaoundé, Cameroon: a randomized trial

Table 3 Assessment of PCR-adjusted therapeutic responses on D7 and D14 (per protocol analysis)

Treatment outcome	Day 7		P-value*	Day 14		P-value*
Treatment outcome	AS-AQ (%)	AL (%)	P-value*	AS-AQ (%)	AL (%)	P-value*
	n = 98	n = 115		n = 98	n = 115
ACPR	95 (96.9)	111 (96.5)	1.000	95 (96.9)	111 (96.5)	1.000
ETF	3 (3.1)	4 (3.5)		3 (3.1)	4 (3.5)
LCF	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)
LPF	0 (0.0)	0 (0.0)		0 (0.0)	0 (0.0)

ACPR Adequate clinical and parasitological response, ETF Early treatment failure, LCF Late clinical failure, LPF Late parasitological failure, AS-AQ Artesunate-amodiaquine, AL Artemether-lumefantrine, n Number of participants followed-up until day 7 or day 14; n values for each row are cumulative (that is, the row 2 n values for ETF do not reflect any new ETFs since day 7, just the cumulative number of ETFs thus far), *Determined using Fisher’s exact test for categorical variables

ISSN: 1471-2334